NetForum uses cookies to ensure that we give you the best experience on our website. If you continue to use the site, we'll assume that you are happy to receive these cookies on the NetForum website. Read about our cookies.
NetForum Community
Learn. Share. Optimize.
Log in | Sign up now | Submit content | Contact

Attention valued NetForum members:

Due to evolving technology needs and global privacy regulations, we have made the hard decision to suspend the NetForum User Community platform on Friday, November 29, 2019.

After this date, the current NetForum can no longer be reached. Please click here for more information about this decision, what happens next and how to stay in touch with us about the future of the community.

Go to similar content

Focal Nodular Hyperplasia

Case Study
Prof. Matos, Celso, M.D. Brussels, Erasme Hospital

Patient history

A 63-year-old female with history of breast cancer presented for an MRI examination on the Achieva 3.0T TX at Erasme Hospital after a focal liver lesion was previously detected with liver US.

MR examination

Achieva 3.0T TX was used with the SENSE Torso XL coil.

Exam included the following sequences:
1. Axial single-shot respiratory triggered TSE T2-weighted with voxel size1.2x1.6x4 mm3; TE 80 ms; TSE factor 62; SENSE acceleration factor 2.
2. Axial respiratory-triggered DWI with multiple b-values (0, 150, 1000 s/mm2); TR 1200 ms; TE 77 ms; voxel size 2.27x2.73x5 mm3; SENSE acceleration factor 2.4)
3. Axial and coronal THRIVE with voxel size 1.49x1.5x3 mm3; TR 3 ms; TE 1.42 ms; SENSE acceleration factor: 2.6)


 DWI b=150 DWI b=1000
DWI b=150
DWI b=1000
 ADC map Delayed e-THRIVE
ADC map
Delayed e-THRIVE

T2-weighted TSE shows a focal liver lesion located in segment 4, hyperintense to adjacent normal liver tissue (arrow).

DWI shows restricted diffusion. The ADC map shows higher ADC of the lesion compared to normal liver.

On delayed coronal THRIVE the lesion enhances relative to adjacent liver, which is related to the presence of functional normal hepatocytes. Combining DWI and contrast-enhanced MRI with liver-specific contrast agents potentially improves the specificity of MRI.


Focal Nodular Hyperplasia.

Clinical impact ofthe Achieva 3.0T TX with MultiTransmit

The Achieva 3.0T TX with MultiTransmit consistently enhances image and contrast uniformity and improves reproducibility which benefits diagnosis and follow-up in oncology patients.

Combining DWI and contrast-enhanced MRI with liver-specific contrast agents potentially improves the specificity of MRI.

Related reading:

This content has been made possible by NetForum Community.
Share this on: Share your link in twitter Share your link in facebook Share your link on LinkedIn Print Rate this article: Log in to vote

Nov 4, 2010

Rate this:
Log in to vote

Case Study
Achieva 3.0T
Release 2, Release 3
Abdomen, Body, DWI, e-THRIVE, FNH, focal nodular hyperplasia, Liver, MultiTransmit, Oncology, SENSE Torso XL coil

Clinical News
Best Practices
Case Studies
Publications and Abstracts
White Papers
Web seminars and Presentations
Application Tips and FAQ
Try an Application
Business News
Case Studies
White Papers
Web Seminars and Presentations
Utilization Services
Contributing Professionals
Contributing Institutions
Become a Contributor